Behind Closed Doors: Medtronic Exec Discusses Dealmaking In China
This article was originally published in PharmAsia News
Medtronic’s dealmaking experience in China sheds light on how multinational players should think about entering China, but time may not be on their side.
You may also be interested in...
As China is poised to supply medical products to fight the coronavirus around the world, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.